Methods for inhibiting cell proliferation in ALK-driven cancers
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 4, 2017
Issued Date -
N/A
app pub date -
Apr 10, 2014
filing date -
Apr 10, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention features a method for treating patients who have an ALK-driven cancer, which is, or has become, refractory to one or more of crizotinib, CH5424802 and ASP3026, or which bears an ALK mutation identified herein, by administering a compound of formula (I) to the patient. The invention also features methods, kits, and compositions for characterizing ALK-driven cancers to determine whether they express an ALK mutant.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully